Skip to main content

IP Roundup: Samsung, Panasonic, U of Illinois, Affymetrix, Illumina, Pathwork Dx

Premium

Samsung Electronics of Seoul, South Korea, has received US Patent No. 8,469,492, "Method of printing droplet using capillary electric charge concentration." The method relies on a capillary nozzle that consists of a back end and a front end. After immersing the back-end part in a solution and supplying a voltage to the solution. The back-end part then transmits the solution to the front-end part.


Samsung has also received US Patent No. 8,470,570, "Apparatus and method for printing biomolecular droplet on substrate." The method is based on an electric charge concentration effect. An electric-field-forming electrode, accommodating micro magnetic beads-containing biomolecular droplets is provided, as is a substrate located below the electrode. By applying a charge to the electric field-forming electrode, an electrical force is generated that causes the biomolecular droplet to be ejected onto the target surface of the substrate.


Panasonic of Osaka, Japan, has received US Patent No. 8,470,162, "Biosensor, thin film electrode forming method, quantification apparatus, and quantification method." The method includes detecting an electrical change generated between a measuring electrode and a counter electrode of a biosensor by applying a sample liquid to the biosensor; detecting an electrical change generated between a detecting electrode of the biosensor and the counter electrode or the measuring electrode by applying the sample liquid to the biosensor; and informing a user when the second step does not occur within a predetermined period after the first detecting step.


The University of Illinois of Urbana has received US Patent No. 8,470,532, "Aptamer-based colorimetric sensor systems." The system provided can be used to determine the presence and optionally the concentration of an analyte in a sample. It relies on combining an aggregate with a sample; and detecting a color change responsive to the analyte in the sample.


Affymetrix of Santa Clara, Calif., has received US Patent No. 8,470,535, "Two stage nucleic acid amplification using an amplification oligomer." The two-stage amplification begins with a first non-enzymatic accumulation of an amplification oligomer that is the target substrate for a second nucleic acid amplification or assay. The two or more amplification oligomers can be used to allow multiplexed amplifications of two or more nucleic acids of interest with deconvolution based on unique detection signals or unique signal locations.


Illumina of San Diego has received US Patent No. 8,470,605, "Optical reader for reading encoded microparticles." According to the patent, each microparticle has an elongated body with an optically detectable code that extends along a longitudinal axis of the corresponding elongated body. The reader includes a plate containing channels that are configured to receive and align the microparticles. The reader also includes a source for illuminating the microparticles on the plate. The codes in the microparticles reflect a portion of incident light and permit a portion of the incident light to pass through the microparticles, providing an output signal indicative of the code.


Pathwork Diagnostics of US Patent No. 8,473,217, "Method and system for standardization of microarray data." The method requires obtaining a test microarray dataset consisting of abundance values for cellular constituents, and applying standardization data structure to the test microarray dataset using a mathematical transformation in order to produce a standardized test microarray dataset.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.